Drug guidance
Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia
Condition
Blood and Immune System
Cancer
1 August 2024
Published on 01 Aug 2024
Last Updated on 01 Aug 2024
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Tisagenlecleucel cells dispersion for infusion for treating patients between two to 25 years of age (both ages inclusive) with B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse.
Funding status
Tisagenlecleucel cells dispersion for infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 August 2024.
Tisagenlecleucel should be used in line with the additional clinical criteria listed in the Annex.